MannKind Corporation (NASDAQ:MNKD) is one of the top strong buy stocks under $5 to buy now. On August 8, Leerink Partners analyst Faisal Khurshid reiterated a Buy rating on MannKind Corporation (NASDAQ:MNKD), keeping the price target at $7.00.
A close-up of a doctor’s hand pressing on an inhaler, conveying the effect of the company’s therapeutic products.
Similarly, in a report released on August 7, Douglas Miehm from RBC Capital maintained a Buy rating on MannKind Corporation with a price target of $7.00.
The same day, Mizuho Securities also released a report maintaining a Buy rating on the stock with a $10.00 price target.
Currently, the analyst consensus on MannKind Corporation is a Strong Buy. The stock’s median price target of $4.11 implies an upside of 118.98% from current levels.
MannKind Corporation is a biopharmaceutical company that develops and commercializes innovative therapeutic devices and products that address serious unmet medical needs for endocrine and orphan lung diseases.
The company’s pipeline and products include Afrezza, Pediatric Afrezza, V-Go, Tyvaso DPI, MNKD-101, MNKD-201, MNKD-301, and MNKD-501.
READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.
This article is originally published at Insider Monkey.
